Lighten the burden of proof.
Demonstrate value
Generate the market-specific evidence you need to go from research to market, overcome regulatory hurdles or support payer approval.
IQVIA provides you with health economic modelling solutions to support market-specific reimbursement, market access and high-impact scientific publications. Beyond data and insights, our local experts can also help you manage health technology assessment bodies around the world. These experts help you shorten timeframes, reduce costs, and lighten operational burdens. IQVIA accelerates your results with
- An international network that can deliver local solutions with global oversight
- Access to the world's most comprehensive non-identified patient-level data and the ability to leverage real world evidence in health economic modelling
- Therapeutic and cross functional expertise (R&D, PMA, Epi, etc.) for scientifically rigorous and commercially relevant solutions
Access a vast network of real world sources
New ways to generate evidence for outcomes research
We are constantly updating our solutions by applying innovative data collection techniques to a wide range of sources, cross-linking de-identified data and closing data gaps. Offerings include classic observational, low interventional clinical studies and innovative approaches such as enriched studies. Advanced analytics give you enhanced ability to determine and quantify benefits, risks, and outcomes.
IQVIA focuses on generating actionable insights that give our clients validated, representative, relevant results. And we bring a strong track record in EMA-accepted Drug Utilization Studies (DUS) in multiple therapy areas and geographies, and experience in working with the FDA, ENCePP, EUnetHTA , MHRA.
With a history of 25 years and more than 5,200 publications and presentations, our bibliography captures real world insights into patients, diseases, treatments, outcomes and costs across virtually all therapeutic areas and projects completed in more than 50 countries.
See how the use of non-identified patient-level data adds depth and granularity to analyses in a specific therapeutic area.
Are usage experience and outcome benefits from person-centered therapeutic innovations appropriately valued?
Get insights into payer decision making and evidence requirements to accelerate market access for your drug.
Use emerging data sources and advances in evidence methods to demonstrate product value and safety.